Specify a stock or a cryptocurrency in the search bar to get a summary
Crossject
ALCJCrossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France. Address: 6 Rue Pauline Kergomard, Dijon, France, 21000
Analytics
WallStreet Target Price
3.99 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALCJ
Dividend Analytics ALCJ
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALCJ
Stock Valuation ALCJ
Financials ALCJ
Results | 2019 | Dynamics |